ELECTRONICALLY REPRINTED FROM MAY[removed]www.PharmExec.com Pharma[removed]

First Page		Document Content
Date: 2013-10-11 15:28:31 Pharmacy Health Pfizer Daiichi Sankyo Eisai Merck KGaA Purdue Pharma Schering AG Mylan Pharmaceutical sciences Pharmacology Pharmaceutical industry		ELECTRONICALLY REPRINTED FROM MAY[removed]www.PharmExec.com Pharma[removed] Add to Reading List Source URL: www.imsconsultinggroup.com Download Document from Source Website File Size: 2,18 MB Share Document on Facebook

	Application of Natural Resources to Drug Discovery in Eisai Research and Development of Eribulin mesylate Katsuya Tagami, Eisai Co., Ltd. Eribuin mesylate is a first-in class, non-taxane microtubule dynamics inhibitor th DocID: 1uZFZ - View Document
	To Whom It May Concern, October 13, 2017 Taisho Pharmaceutical Co., Ltd. Eisai Co., Ltd. Toyama Chemical Co., Ltd. DocID: 1ugwQ - View Document
	11. Major R&D Pipeline In-House R&D Pipeline List Additional Indication, etc.** Product Name / Development Code DocID: 1sXjF - View Document
	ご使用に際して、この説明書を必ずお読みください。また、必要な時に読めるよう大切に保管してください。メコバラミン主薬製剤第3類医薬品 DocID: 1sWWa - View Document
	June 17, Koishikawa, Bunkyo-ku, Tokyo Eisai Co., Ltd. Director, Representative Corporate Officer and CEO Haruo Naito Dear shareholders: DocID: 1siNy - View Document